Carlsbad, California, December 17, 2015 /Marketwired/ - Aurora Spine Corporation (TSXV: ASG) announced today that more than 1,000 ZIP® MIS Interspinous Fusion Devices have now been implanted in patients around the world undergoing spinal fixation procedures. "Surpassing 1,000 ZIP MIS Interspinous Fusion implants is a milestone achievement for Aurora Spine. The ZIP implant is rapidly becoming the new standard of care for minimally invasive posterior fusion," said Trent Northcutt, Aurora Spine’s President and CEO.

The ZIP is Aurora Spine's minimally invasive interspinous fixation implant family for spinal fusion and was developed as an alternative to pedicle screw fixation. The ZIP implant is designed for stabilization and load sharing in T1-S1spinal fusion procedures as an adjunct to interbody fusion, specifically for the treatment of degenerative disc disease, spondylolisthesis, trauma, and/or tumor. The proprietary ZIP ONE-STEPTM locking mechanism eliminates the use of a set screw. The ZIP product family includes the ZIP ULTRA®, the ZIP LPTM low profile and the ZIP 51 sacral implant.

“The ZIP MIS Interspinous Fusion implant has been used in the United States, Canada, Europe and the Middle East to treat spinal disorders that have been treated in the past using mostly pedicle screw constructs,” said Laszlo Garamszegi, Chief Technology Officer. “Our R&D goal is to provide even more possibilities for simpler and less painful fusion procedures,” Garamszegi said.

About Aurora Spine

Aurora Spine is an early stage company focused on bringing new solutions to the spinal implant market through a series of screwless, innovative, minimally invasive, regenerative spinal implant technologies. Aurora Spine continues to position itself at the forefront of spinal surgery procedures, focusing on minimally invasive spine surgery technologies. Aurora Spine is changing spine surgery by focusing on disruptive technologies following the Company’s commitment to – Simplifying the Complex.

Forward-Looking Statements

This news release contains forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurora Spine, including, without limitation, those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Information" in Aurora Spine's final prospectus (collectively, "forward-looking information"). Forward-looking information in this news release includes information concerning the proposed use and success of the company’s products in surgical procedures. Aurora Spine cautions investors of Aurora Spine's securities about important factors that could cause Aurora Spine's actual results to differ materially from those projected in any forward-looking statements included in this news release. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ unilaterally from those expressed in such forward-looking statements. No assurance can be given that the expectations set out herein will prove to be correct and, accordingly, prospective investors should not place undue reliance on these forward looking statements. These statements speak only as of the date of this press release and Aurora Spine does not assume any obligation to update or revise them to reflect new events or circumstances.

For more information, please contact:

Aurora Spine Corporation

Trent Northcutt

President and Chief Executive Officer

(760) 424-2004

Eric Fronk

Chief Financial Officer

(760) 424-2004

Christian Flores